The first and only treatment for a rare and often fatal blood cell disorder has been approved in the United States.
A discussion of various treatments and therapies for gastric cancer, including HER2+ advanced gastric/GEJ cancer.
Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, non–small cell lung, and other cancers.
Study investigators develop a predictive model to predict the mortality hazard of DLBCL patients within 2 years of treatment.
Recent studies suggest that the immune microenvironment plays a role in treatment response prediction and survival in DLBCL.
This study evaluates the long-term course of hematologic recovery, immune reconstitution, and infectious complications in 41 patients with LBCL treated with axicabtagene ciloleucel at a single center.